RCN Pareto Strategic Allocation ETF (NYSEARCA:PRTO) Short Interest Update

RCN Pareto Strategic Allocation ETF (NYSEARCA:PRTO) saw a significant increase in short interest during the month of July. As of July 31st, there was short interest totaling 1,444 shares, an increase of 618.4% from the July 15th total of 201 shares. Based on an average daily trading volume, of 3,592 shares, the short-interest ratio is currently 0.4 days. Currently, 0.0% of the shares of the company are short sold.

RCN Pareto Strategic Allocation ETF Trading Up 0.1%

PRTO stock opened at $28.42 on Friday. RCN Pareto Strategic Allocation ETF has a 1-year low of $24.68 and a 1-year high of $28.42. The company has a market cap of $630.33 million, a P/E ratio of -29.60 and a beta of 0.60.

Proteon Therapeutics was a biopharmaceutical company focused on developing treatments for patients with kidney and vascular diseases. The company’s research and development efforts centered on therapies designed to address severe and life-threatening conditions, particularly those related to renal disease and vascular access for hemodialysis patients.

One of Proteon Therapeutics’ best-known product candidates was vonapanitase, an investigational enzyme developed to improve vascular access outcomes in patients with end-stage renal disease who require hemodialysis.